NeoImmuneTech to Present at Upcoming Scientific/Medical Conferences
ROCKVILLE, Md.--(BUSINESS WIRE)-- NEOIMMUNETECH, INC, a clinical-stage T cell-focused biopharmaceutical company, today announced that the company will present data at multiple upcoming scientific/medical conferences. These include three poster presentations at the Society for Immunotherapy of Cancer (SITC) annual meeting, occurring November 10-15, and an oral presentation at the Society for Neuro-Oncology (SNO) annual meeting, occurring November 19-22. Details of the presentations are as follows:
Title: Efficacy and safety of GX-I7 plus pembrolizumab for heavily pretreated patients with metastatic triple negative breast cancer: The Phase 1b/2 KEYNOTE-899 Study.
Poster Number: 322
Category: In-Progress Clinical Trials
Title: Combination of rhIL-7-hyFc and anti-PD-L1xCD3ε bispecific antibody enhances antitumor response in mice.
Poster Number: 450
Category: Combination Immunotherapies
Title: A novel long-acting interleukin-7 agonist, NT-I7, increases cytotoxic CD8+ T cells and enhances survival in mouse glioma models.
Poster Number: 565
Category: Immune-stimulants and immune modulators
Date/Time: All odd numbered posters will be presented on Wednesday, Nov. 11, from 5:15-5:45 p.m. EST and Friday, Nov. 13, from 4:40-5:10 p.m. EST. Even numbered posters will be presented on Thursday, Nov. 12, from 4:50-5:20 p.m. EST and Saturday, Nov. 14, from 1-1:30 p.m. EST.
Posters will be on display from 8 a.m. on Monday, Nov. 9, until the virtual poster hall closes on December 31, 2020.
Title: A novel long-acting interleukin-7 agonist, NT-I7, increases cytotoxic CD8 cells and enhances survival in mouse glioma models
Session Number: EXTH-14
Session Name: Experimental and Translation Sciences Session III
Date/Time: On demand
NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7, and is being developed for oncologic and immunologic indications, in which T cell amplification and increased functionality may provide clinical benefit. IL-7 is a fundamental cytokine for naïve and memory T cell development and for sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases). NT-I7 exhibits favorable PK/PD and safety profiles, making it an ideal combination partner. NT-I7 is being studied in multiple clinical trials in solid tumors and as a vaccine adjuvant. Studies are being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications.
NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company, dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. NIT is led by the scientific founder and inventor of NT-I7 (efineptakin alfa) and complemented by a strong executive team with rich industry experience at companies such as Novartis, BMS, GSK, Pfizer, Amgen, Eli Lilly, MedImmune/AstraZeneca and PwC. NIT is expanding rapidly in personnel and operations, as well as partnering with industry and academic leaders to investigate NT-I7 as monotherapy and in combination with various immunotherapeutics. For more information, please visit www.neoimmunetech.com.
Source: NeoImmuneTech, Inc.